oral fluids
OtherAny fluid volume prescribed by the physician during the ED stay is administered orally.
NCT Number: NCT07361952
The goal of this randomized clinical feasibility trial is to determine whether oral fluid therapy can achieve prescribed fluid volumes as effectively as intravenous fluid therapy in adult patients admitted to the emergency department who require fluid treatment.
The main questions it aims to answer are:
Are patients receiving oral fluids equally likely to achieve the prescribed fluid volume compared with patients receiving intravenous fluids?
Is it feasible to conduct a randomized trial of oral versus intravenous fluid therapy in the emergency department, based on recruitment rate and protocol adherence?
Researchers will compare oral tap water administration with standard intravenous crystalloid therapy to assess whether oral fluids are non-inferior in achieving prescribed fluid volumes and to evaluate feasibility outcomes.
Participants will:
Be randomized to receive either oral tap water or intravenous crystalloid fluids during their stay in the emergency department
Receive a fluid volume and administration rate determined by the treating physician
Be monitored according to standard clinical practice during the emergency department stay
Have fluid intake, vital signs, and clinical outcomes recorded, with follow-up through routine health records up to 30 days after inclusion
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Emergency Department, South Jutland Hospital, Aabenraa, Denmark
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Any fluid volume prescribed by the physician during the ED stay is administered orally.
Any fluid volume prescribed by the physician during the ED stay is administered intravenously.
Time frame: From inclusion until end of participation. End of participation is defined as the timepoint of leaving the emergency department or after 48 hours, whichever happens first.
Time frame: From inclusion to end of participation (defined as ED stay or maximum of 48 hours), unless mentioned otherwise
Intravenous fluids, oral fluids, total fluids
Time frame: From inclusion to end of participation (defined as ED stay or maximum of 48 hours), unless mentioned otherwise
Intravenous fluids, oral fluids, total fluids
Time frame: 8 hours or discharge, whatever comes first.
Time frame: 30 days
Time frame: 30 days
Time frame: From inclusion to end of participation (defined as ED stay or maximum of 48 hours), unless mentioned otherwise
Esbjerg Hospital - University Hospital of Southern Denmark
Other
Acronym: OVID-B
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07052461
Cardiovascular Diseases, Fluid Management
Basel, Switzerland
View Trial DetailsNCT07366164
Fluid Management, Hemodynamic (MAP) Stability
Roma, RM, Italy
View Trial DetailsNCT07258875
Acute Kidney Injury, Female Urogenital Diseases
Heraklion, Crete, Greece
View Trial DetailsNCT07633600
Fluid Management, Kidney Transplant
Los Angeles, California, United States
View Trial Details